Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients

BACKGROUND: The effect of palliative chemotherapy for non-small cell lung cancer (NSCLC) is well established. Recently, immune checkpoint inhibitors have shown promising efficacy in NSCLC patients. However, little is known about the efficacy of cytotoxic chemotherapy in patients whose tumors are ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothschild, S.I., Nachbur, R., Herzog, N., Passweg, J.R., Pless, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809381/
https://www.ncbi.nlm.nih.gov/pubmed/33422767
http://dx.doi.org/10.1016/j.esmoop.2020.100013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809381/
https://www.ncbi.nlm.nih.gov/pubmed/33422767
http://dx.doi.org/10.1016/j.esmoop.2020.100013

Ejemplares similares